AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00770107
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
Trial: NCT00770107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, for a duration of 4 weeks
Trial: NCT04272580
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preload was given before spinal anesthesia.
Trial: NCT04272580
Drug: 4 ml/kg group.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Trial: NCT04272580
Drug: 8 ml/kg group.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Trial: NCT04272580
Drug: 12 ml/kg group.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Trial: NCT01792479
Drug: BIND-014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02798510
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01519531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
Trial: NCT02623322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a single dose by IV administration.
Trial: NCT04466748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
Trial: NCT03232983
Drug: LY900014 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01973660
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole or tamoxifen will be prescribed according to patient's menopausal status
Trial: NCT01641393
Drug: EUR-1008 25,000 Units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
Trial: NCT01641393
Drug: Kreon 25,000 Units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
Trial: NCT01687257
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF 400 mg tablet administered orally once daily
Trial: NCT05343780
Drug: Heptex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dukung Anak 200 mg + Milk thistle 100 mg
Trial: NCT00180635
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml
Trial: NCT01218126
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparison with active
Trial: NCT02549469
Drug: Naproxen Sodium ER (BAY117031), 30% HPMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 660 mg administered orally once daily
Trial: NCT02549469
Drug: Naproxen Sodium ER (BAY117031), 40% HPMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 660 mg administered orally once daily
Trial: NCT00443937
Drug: enteric-coated mycophenolate sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04681729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Trial: NCT02803268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01860703
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin-matching placebo
Trial: NCT02678312
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
Trial: NCT02678312
Drug: Placebo of LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02678312
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
Trial: NCT00818961
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
Trial: NCT00818961
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 administered on days +1, +3 and +6
Trial: NCT00753792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
Trial: NCT01918735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control matched to the oral or intravenous experimental comparator drug
Trial: NCT01918735
Drug: GWP42006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects.
Trial: NCT02137161
Drug: Dexamethasone+Tobramycin eye drop
RxNorm normalized name: dexamethasone / tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
Trial: NCT02137161
Drug: Bromfenac eye drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromfenac ophthalmic solution 0.09%
Trial: NCT01936025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04609033
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: instillation of local anaesthetic in the abdominal cavity at the end of the procedure
Trial: NCT06069219
Drug: Epidural administration of sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
Trial: NCT02306759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 50ml, administered over 15 minutes
Trial: NCT02666547
Drug: 68Ga-NODAGA-RGD PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
Trial: NCT02170740
Drug: BIBR 1048 MS - high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03503266
Drug: [14C] MT-7117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-C MT-7117
Trial: NCT01831622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
Trial: NCT02215122
Drug: MGR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Trial: NCT02215122
Drug: Advair® Diskus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Trial: NCT02215122
Drug: Seretide™ Accuhaler™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Trial: NCT04881006
Drug: Farxiga® 10 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured by AstraZeneca Pharmaceuticals LP
Trial: NCT00686881
Drug: Comparator: Stronger neo minophagen C (SNMC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
Trial: NCT02616874
Drug: MVA.HIVconsv vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
Trial: NCT00003500
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01951638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00030030
Drug: Silymarin (milk thistle)
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02660866
Drug: Placebo + background APT + SMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Trial: NCT06733506
Drug: Isopropyl Alcohol 70% Topical Application Solution
RxNorm normalized name: Isopropyl Alcohol 70% Topical application Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
Trial: NCT02173548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04657744
Drug: Sphingomod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule contains 0.5 mg Fingolimod
Trial: NCT00549757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match aliskiren 150 mg film-coated tablets
Trial: NCT04984707
Drug: KX0826
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR antagonist
Trial: NCT00258258
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02591238
Drug: non-smoker oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Trial: NCT02591238
Drug: smoker oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Trial: NCT02899325
Drug: Diagnostic PET/CT scans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
Trial: NCT00002611
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002611
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
Trial: NCT03813238
Drug: TEV-50717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage ranging from 6 mg to 48 mg.
Trial: NCT03813238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage ranging from 6 mg to 48 mg.
Trial: NCT02398929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be given once daily for 2 weeks during the run-in period.
Trial: NCT01494987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ranolazine for the duration of the study
Trial: NCT01335867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills
Trial: NCT02565914
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose tablet for oral administration.
Trial: NCT03080805
Drug: Pyrotinib Plus Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
Trial: NCT03080805
Drug: Lapatinib Plus Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
Trial: NCT02031198
Drug: AADvac1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunization against pathological Alzheimer's disease tau protein
Trial: NCT02642250
Drug: Entoban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
Trial: NCT04525495
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine treatment
Trial: NCT00644631
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
Trial: NCT02905825
Drug: BreathID® Hp Lab System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Trial: NCT01578811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage
Trial: NCT01009918
Drug: Coreg CR®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03546894
Drug: Any FDA Approved ALK Inhibitors
RxNorm normalized name: Anaplastic lymphoma kinase (ALK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved ALK inhibitors available for treatment.
Trial: NCT01094925
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT02972957
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
Trial: NCT01588626
Drug: AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01934933
Drug: Enbrel plus Celebrex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02246127
Drug: STZ-5FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT00028106
Drug: [131]I-MIBG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00028106
Drug: 6-[18F]Fluorodopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00028106
Drug: [123]I-MIBG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01797445
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Trial: NCT01797445
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Trial: NCT01797445
Drug: E/C/F/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT01797445
Drug: E/C/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT00796250
Drug: Placebo Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
Trial: NCT00796250
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
Trial: NCT01136863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01016080
Drug: glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg capsules, twice daily, orally
Trial: NCT01016080
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg capsules, twice daily, orally
Trial: NCT00264420
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
Trial: NCT01911728
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00107250
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
Trial: NCT02533401
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Trial: NCT02448251
Drug: AC0010MA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
Trial: NCT04259450
Drug: 480 mg AFM24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Trial: NCT04475549
Drug: IW-6463 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-6463 tablets administered orally (daily)
Trial: NCT04252742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 consecutive injections
Trial: NCT01011621
Drug: 0.5% prednisolone acetate cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied over the lesion twice a day for 14 days.
Trial: NCT01717066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02474914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide will NOT be given after PD
Trial: NCT02195986
Drug: Estradiol Vaginal Cream, 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
Trial: NCT02195986
Drug: Estrace® 0.01% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
Trial: NCT02195986
Drug: Placebo Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Vaginal Cream ( 1 x 2 g for 7 days)
Trial: NCT02782169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule with excipient to match Pregabalin
Trial: NCT00771810
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous injection of 100 ug/kg
Trial: NCT00771810
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous injection of 300 ug/kg
Trial: NCT00771810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous injection of placebo
Trial: NCT02303184
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprachoroidal sham procedure
Trial: NCT00566683
Drug: diazemuls, pethidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine